Single cells in close contact with the trophoblastic layer were found to express VE-cadherin and PECAM-1 and also showed strong angiogenin expression.
Despite the functional similarity between angiogenin and VEGF, there have been few studies to date that have investigated angiogenin expression and regulation in ALS.
Treatment of endothelial cells with ruPA increased angiogenin secretion and angiogenin expression as determined by ELISA and western blotting in a dose-dependent manner.
The present study has shown that ruPA ATF blocks angiogenin secretion in endothelial cells, and it significantly inhibits ruPA-induced angiogenin expression in a dose-dependent manner.
Angiogenin expression is likely to be important in the pathogenesis of ALS.
There is evidence of dysregulation of angiogenin expression in plasma and CSF in sporadic ALS.
We have sought to determine (i) whether angiogenin is detectable in CSF, (ii) whether there is a consistent relationship between plasma and CSF angiogenin levels, (iii) whether genetic variations in the ANG locus control angiogenin expression, and (iv) whether, as has been reported for VEGF [9] [11], there is a dysregulation of angiogenin in sporadic ALS.
This could be due to a number of factors, including perturbation of angiogenin transport in ALS, however an interesting possibility could be micro RNA (miRNA) regulation of angiogenin expression.
To check if uPA ATF, which includes the GFD and the kringle domain, plays a role in angiogenin expression and secretion, we first treated endothelial cells with different concentrations of ruPA for 24 hrs, then treated with ruPA ATF, and assayed for angiogenin expression by western blotting and angiogenin secretion by ELISA.
We have shown that this correlation is lost in ALS patients (p = 0.21 for patients), which may suggest a tissue-specific dysregulation of angiogenin expression in ALS.
